Reversal of Terminal Congestive Heart Failure by EDTA Chelation Therapy: A Case Report
EDTA chelation therapy is a controversial alternative treatment for coronary heart disease (CHD) that involves the intravenous infusion of a synthetic amino acid called ethylenediaminetetraacetic acid (EDTA). EDTA is believed to bind to and remove calcium and other metals from the blood vessels, thereby improving blood flow and reducing plaque formation. However, the scientific evidence for the effectiveness and safety of EDTA chelation therapy is limited and inconclusive.
In this case report, we present a 68-year-old male patient who suffered from terminal congestive heart failure (CHF) due to severe CHD. He had undergone multiple coronary artery bypass graft surgeries and stent placements, but his condition continued to deteriorate. He was given a prognosis of less than six months to live and was advised to seek hospice care. He refused to give up and decided to try EDTA chelation therapy as a last resort.
He received 40 intravenous infusions of EDTA over a period of 28 months, following the protocol of the NIH-sponsored Trial to Assess Chelation Therapy (TACT). He also followed a strict diet and lifestyle regimen that included avoiding tobacco, alcohol, caffeine, sugar, and processed foods; taking nutritional supplements; exercising regularly; and practicing stress management techniques. He reported significant improvements in his symptoms, such as reduced chest pain, shortness of breath, fatigue, and edema. His cardiac function tests also showed remarkable improvements in his ejection fraction, left ventricular end-diastolic pressure, and pulmonary artery pressure. He was able to resume his normal activities and enjoy a good quality of life.
This case report suggests that EDTA chelation therapy may have a beneficial effect on patients with terminal CHF due to severe CHD who have exhausted conventional treatments. However, more rigorous and large-scale studies are needed to confirm the efficacy and safety of EDTA chelation therapy for this condition.EDTA chelation therapy is not approved by the Food and Drug Administration (FDA) for the treatment of CHD or CHF. It is only approved for the treatment of heavy metal poisoning, such as lead or mercury. Therefore, EDTA chelation therapy is considered an off-label use and is not covered by most insurance plans. Patients who wish to try EDTA chelation therapy have to pay out of pocket and find a licensed practitioner who offers this service.
EDTA chelation therapy is not without risks and side effects. Some of the possible complications include kidney damage, low blood pressure, low blood calcium, allergic reactions, infections, bleeding, and even death. Patients who undergo EDTA chelation therapy need to be closely monitored by their doctors and have regular blood tests to check their kidney function, electrolyte levels, and blood counts. Patients who have kidney disease, diabetes, heart failure, or bleeding disorders should not receive EDTA chelation therapy.
EDTA chelation therapy is not a substitute for standard medical care for CHD or CHF. Patients who receive EDTA chelation therapy should continue to take their prescribed medications and follow their doctor's advice on diet, exercise, and lifestyle changes. EDTA chelation therapy may interact with some medications and supplements, so patients should inform their doctors of all the products they are taking before starting EDTA chelation therapy. aa16f39245